Clinical impact of muscle-related adverse events in patients receiving sonidegib: 42-Month BOLT results
We examined the clinical impact of sonidegib 200 mg muscle-related AEs based on 42 m data from BOLT, the randomized, double-blind, multicenter, registration Phase 2 study of sonidegib for the treatment of locally advanced (laBCC) or metastatic BCC (mBCC; NCT01327053).
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research
More News: Academies | Basal Cell Carcinoma | Cancer & Oncology | Carcinoma | Dermatology | Skin | Skin Cancer | Study